drugset / Trial / NCT07172867

A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM

NCT07172867

Phase 2 Withdrawn Halia Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of ofirnoflast in combination with semaglutide in comparison to semaglutide alone in obese participants with T2DM.

Timeline

Start
2026-01-06
Primary completion
2026-01-23
Completion
2026-01-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Ofirnoflast Small molecule 2 mg Oral
Background Semaglutide Peptide 1 mg Subcutaneous